

---

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**

**CURRENT REPORT**  
**Pursuant to Rule 13 or 15(d)**  
**of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported):  
**July 30, 2019**

---

**CRH MEDICAL CORPORATION**

(Exact name of registrant as specified in its charter)

---

**British Columbia, Canada**  
(State or other jurisdiction  
of incorporation)

**001-37542**  
(Commission File Number)

**Not Applicable**  
(IRS Employer  
Identification No.)

**Suite 578 - 999 Canada Place, World Trade Center, Vancouver,**  
**British Columbia, Canada**  
(Address of principal executive offices)

**V6C 3E1**  
(Zip Code)

**(604) 633-1440**  
(Registrant's telephone number, including area code)

**Not Applicable**  
(Former name of former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

**ITEM 7.01 REGULATION FD DISCLOSURE**

On July 30, 2019, CRH Medical Corporation issued a press release regarding its participation in the 2019 Canaccord Genuity Growth Conference. A copy of the press release is being furnished herewith as Exhibit 99.1.

The information provided under this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

**ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS**

**(d) Exhibits**

Exhibit

**No.            Description**

[99.1](#)            [Press Release issued by CRH Medical Corporation on July 30, 2019](#)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

***CRH MEDICAL CORPORATION***

---

(Registrant)

Date: July 30, 2019

By: /s/ Richard Bear

Name: Richard Bear

Title: Chief Financial Officer

## CRH Medical Corporation to Present at the Canaccord Genuity Growth Conference

VANCOUVER, July 30, 2019 /CNW/ - **CRH Medical Corporation** (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), announces that it will participate in the 2019 Canaccord Genuity Growth Conference at the Intercontinental Hotel in Boston, Massachusetts.

Tushar Ramani, Chief Executive Officer of the Company and Richard Bear, Chief Financial Officer of the Company, are scheduled to present on Thursday, August 8<sup>th</sup> at 9:30 am ET. A webcast of the presentation will be available at <http://wsw.com/webcast/canaccord35/crhm/>. The webcast will be accessible for two weeks following the event.

For more details about the conference, please visit <http://growthconference.canaccordgenuity.com>.

### **About CRH Medical Corporation:**

CRH Medical Corporation is a North American company focused on providing gastroenterologists throughout the United States with innovative services and products for the treatment of gastrointestinal diseases. In 2014, CRH became a full-service gastroenterology anesthesia company that provides anesthesia services for patients undergoing endoscopic procedures in ambulatory surgical centers. To date, CRH has completed 23 anesthesia acquisitions. CRH now serves 52 ambulatory surgical centers in 11 states and performs approximately 333,000 procedures annually. In addition, CRH owns the CRH O'Regan System, a single-use, disposable, hemorrhoid banding technology that is safe and highly effective in treating all grades of hemorrhoids. CRH distributes the O'Regan System, treatment protocols, operational and marketing expertise as a complete, turnkey package directly to gastroenterology practices, creating meaningful relationships with the gastroenterologists it serves. CRH's O'Regan System is currently used in all 48 lower US states.

View original content:<http://www.prnewswire.com/news-releases/crh-medical-corporation-to-present-at-the-canaccord-genuity-growth-conference-300892505.html>

SOURCE CRH Medical Corporation

View original content:  
<http://www.newswire.ca/en/releases/archive/July2019/30/c9966.html>

%CIK: 0001461119

**For further information:** CRH Medical Corporation, Richard Bear, Chief Financial Officer, 425-658-0151, [rbear@crhmedcorp.com](mailto:rbear@crhmedcorp.com), <http://investors.crhsystem.com/>

CO: CRH Medical Corporation

CNW 08:30e 30-JUL-19